Testing ALK-targeted pills for ALK-positive advanced squamous cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to the study and sign an informed consent form.
- You are 18 years or older.
- Your squamous cell cancer is confirmed and has either spread or progressed, and you have not had cancer medicines for it yet.
- Your tumor test shows an ALK gene fusion (by a pathology test like IHC, NGS, or FISH).
- Your overall health is good enough for treatment (ECOG 0 to 1) and you are expected to live at least 12 weeks.
- You have at least one measurable tumor spot and blood/organ tests are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
This study tests a new pill (SY-3505) compared to the standard first treatment (crizotinib) for people with ALK-positive advanced lung cancer that hasn't been treated yet. If you qualify, you'd be randomly assigned to one of these two oral medicines, and the study will see which one works better.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This Phase 2 trial tests pembrolizumab (an immune therapy), bevacizumab (a medicine that blocks blood-vessel growth), and chemotherapy in people with ALK-rearranged lung cancer that is still present after the first treatment with alectinib. It aims to shrink tumors and improve control of the cancer.
This study tests two targeted pills, crizotinib and alectinib, for people with advanced bone cancer that has a specific gene change called ALK. These medicines block the ALK protein, which may help shrink or slow the cancer if standard treatments have stopped working.
This trial tests a new drug called ALK201 combined with an immunotherapy drug (ivonescimab) for people with squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and is safe.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.